TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21824041

Group type: EXPERIMENTAL
Intervention: Dash® device with a display fixed on the cutting blocks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Kolibri® device with an external display
Number of subjects: 30
Study: 19470696

Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg orally twice a day for the first 21 consecutive days in 28-day cycles
Number of subjects: 457

Group type: COMPARATOR
Intervention: Best supportive care (BSC), including hydroxyurea
Number of subjects: 457
Study: 17291792

Group type: EXPERIMENTAL
Intervention: VR iliac training module (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VR renal training module (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crossover performance of group B (renal trained) on simulated iliac task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crossover performance of group A (iliac trained) on simulated renal task
Number of subjects: 20
Study: 15209646

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg four times a day (qid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo administered qid with acetaminophen as needed (prn)
Number of subjects: 39
Study: 11207351

Group type: EXPERIMENTAL
Intervention: Hypothermia (body temperature, 33 degrees C)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 392
Study: 9625044

Group type: EXPERIMENTAL
Intervention: %CDT TIA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CDTect
Number of subjects: 204
Study: 8120721

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP until resolution of lung disease
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 6 hours of nasopharyngeal CPAP
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oxygen supplementation delivered by hood
Number of subjects: 124
Study: 2535953

Group type: EXPERIMENTAL
Intervention: Radiation plus ACNU (30 mg/m2 x 4 times during irradiation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Radiation alone (50 to 60 Gy/5 to 6 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Radiation plus ACNU
Number of subjects: 77

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 77
Study: 792861

Group type: EXPERIMENTAL
Intervention: Mianserin ('Bolvidon') at an average dose of 40 mg a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine at an average dose of 100 mg a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mianserin, Imipramine, and Placebo
Number of subjects: 0
Study: 31488314

Group type: EXPERIMENTAL
Intervention: Roluperidone 32 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Roluperidone 64 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 30886125

Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (0.1‐6.4 mg) for up to 14 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (2 mg, once daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib
Number of subjects: 56
Study: 28926159

Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (1 mg/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intranasal Fentanyl (1.5 μg/kg)
Number of subjects: 87
Study: 25913538

Group type: EXPERIMENTAL
Intervention: Escitalopram (24-week double blind trial)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Placebo (24-week double blind trial)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Medical treatment as usual
Number of subjects: 1152
Study: 24282229

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (40 mg, 3 times per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (identical-appearing tablets)
Number of subjects: 35
Study: 21106284

Group type: EXPERIMENTAL
Intervention: 5-session video-based, small group, cognitive-behavioral, HIV prevention intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: 5-session video-based, contact-matched, HIV education control condition
Number of subjects: 346
Study: 19143751

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not treated with pravastatin)
Number of subjects: 48
Study: 17695377

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 3552
Study: 15197285

Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial treatment (comprehensive intervention with counseling, support, and consultation)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial treatment
Number of subjects: 320
Study: 11773290

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy (including chemotherapy and tamoxifen)
Number of subjects: 10000
Study: 9613308

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study: 8293412

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 259

Group type: COMPARATOR
Intervention: Metoclopramide-dexamethasone cocktail
Number of subjects: 259
Study: 2657424

Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of baclofen
Number of subjects: 20
Study: 29750023

Group type: EXPERIMENTAL
Intervention: ADL training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Multicomponent aerobic and strength exercise training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combined ADL and exercise training
Number of subjects: 87

Group type: COMPARATOR
Intervention: ADL training, multicomponent aerobic and strength exercise training, combined ADL and exercise training
Number of subjects: 87
Study: 28877756

Group type: EXPERIMENTAL
Intervention: Jigsaw puzzle group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive health counseling group
Number of subjects: 100
Study: 25790022

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (650 mg of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (10 g of margarine daily without EPA/DHA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation
Number of subjects: 79
Study: 23639186

Group type: EXPERIMENTAL
Intervention: Screen-positive for at least one anxiety disorder (n=114)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Number of screen-positive anxiety conditions (1, 2, ≥3)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Screen-positive anxiety conditions after adjusting for major depression
Number of subjects: 250
Study: 21427155

Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise training (TWET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overground walking exercise training (OWET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional physiotherapy rehabilitation (Control)
Number of subjects: 60
Study: 18499184

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U intradetrusor injection)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16513663

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PPCI)
Number of subjects: 7743

Group type: COMPARATOR
Intervention: Fibrinolysis (FL)
Number of subjects: 7743
Study: 12920410

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram (20 mg/d)
Number of subjects: 0
Study: 10966968

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined drug administration
Number of subjects: 34
Study: 10187002

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (no tramadol)
Number of subjects: 142
Study: 7825505

Group type: EXPERIMENTAL
Intervention: 0.3% S-1033 solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.4% S-1033 solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.3% S-1033 solution (multiple-dose study)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle solution (control)
Number of subjects: 6
Study: 3344931

Group type: EXPERIMENTAL
Intervention: Cow milk formula feeding before normal breastfeeding (n = 112)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Breastmilk feeding (n = 104)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cow milk formula feeding (n = 112)
Number of subjects: 216
Study: 29270836

Group type: EXPERIMENTAL
Intervention: MCP block (20 ml of ropivacaine 0.2%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ISP block (20 ml of ropivacaine 0.2%)
Number of subjects: 8
Study: 28532529

Group type: EXPERIMENTAL
Intervention: Nutrition counselling intervention (exclusive breast-feeding until 6 months, continued breast-feeding supplemented by protein-, lipid-, and carbohydrate-rich foods until age 2 years)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (routine feeding advice)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Nutrition counselling intervention
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study: 26284410

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously before anesthetic induction)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 280
Study: 23124783

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 714

Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 714
Study: 20805297

Group type: EXPERIMENTAL
Intervention: MTX + IAST
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 40
Study: 18484560

Group type: EXPERIMENTAL
Intervention: Insulin glargine (n=16)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (saline; n=5)
Number of subjects: 21
Study: 17699258

Group type: EXPERIMENTAL
Intervention: Low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard-dose RATG (2 mg/kg per d)
Number of subjects: 33
Study: 12729882

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 65
Study: 11115442

Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg bid
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus titrated theophylline bid
Number of subjects: 80
Study: 9099188

Group type: EXPERIMENTAL
Intervention: 1 microgram 1 alpha (OH)D3 daily + 300 mg elemental calcium
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inactive placebo + 300 mg elemental calcium
Number of subjects: 64
Study: 8232358

Group type: EXPERIMENTAL
Intervention: Milacemide at a starting dose of 2,400 mg/day, increased to a maximum of 4,800 mg/day
Number of subjects: 10
Study: 3552455

Group type: EXPERIMENTAL
Intervention: Lignocaine (5%) spray
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cinchocaine (2%) spray
Number of subjects: 76

Group type: COMPARATOR
Intervention: Water-only placebo spray
Number of subjects: 76
Study: 31209271

Group type: EXPERIMENTAL
Intervention: Starved treatment (no food)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Fed treatment (ad libitum access to food)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (second study)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-alcohol consumption (second study)
Number of subjects: 84
Study: 29331959

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27038045

Group type: EXPERIMENTAL
Intervention: Pre-Surgical Exercise Training (PreSET) - endurance and strength training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 25071343

Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT, 600 mg/d)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM, 100 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both groups (LDT and LAM)
Number of subjects: 52
Study: 24304478

Group type: EXPERIMENTAL
Intervention: Self-weighing twice a day with daily target setting and feedback (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-weighing once a day (group 1)
Number of subjects: 60
Study: 20679147

Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 7.5 mg of elemental iron per liter (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 10 mg of elemental iron per liter (group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 5 mg of elemental iron per liter (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Bixa orellana) (group D)
Number of subjects: 0
Study: 18806533

Group type: EXPERIMENTAL
Intervention: Ibandronate (6 mg infusions administered on each of 3 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 10
Study: 15995051

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tympanostomy tubes
Number of subjects: 217

Group type: COMPARATOR
Intervention: Tympanostomy tubes only (Control)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 217
Study: 12689976

Group type: EXPERIMENTAL
Intervention: Counselling on physical activity (green prescription programme)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 878
Study: 10569217

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (PerMamma Abbott) providing 20mg zinc sulfate, 2mg copper sulfate, and 116 microg potassium iodide.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional Italian diet without vitamin and mineral supplements.
Number of subjects: 32
Study: 8724709

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1860094

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg once daily (increased to 20 mg if needed)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 80
Study: 6352643

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 55

Group type: COMPARATOR
Intervention: Penicillin and Gentamicin
Number of subjects: 55
Study: 30997967

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27993381

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (under 100 mEq sodium diet) in Study A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (under 100 mEq sodium diet) in Study B
Number of subjects: 0
Study: 25642682

Group type: EXPERIMENTAL
Intervention: physical practice + PETTLEP imagery (PP+PI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: physical practice + traditional imagery (PP+TI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: physical practice only (PP)
Number of subjects: 36
Study: 25202068

Group type: EXPERIMENTAL
Intervention: Cryotherapy followed by surgical excision
Number of subjects: 10

Group type: COMPARATOR
Intervention: Surgical excision alone
Number of subjects: 10
Study: 22459448

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview with booster
Number of subjects: 889

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 889
Study: 20879046

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Eccentric group of both SES and PES
Number of subjects: 301
Study: 17619207

Group type: EXPERIMENTAL
Intervention: Acupuncture at specific points (colon 4 bilateral, liver 3 bilateral, urinary bladder 23 bilateral, gall bladder 25 contralateral to the stone, circulation 6 bilateral, Ren Mai)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Analgesics (50 mg pethidine and 10 mg diazepam)
Number of subjects: 102
Study: 15899018

Group type: EXPERIMENTAL
Intervention: Transmandibular implant-retained overdentures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Four endosseous implants following augmentation of the mandible
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Four short endosseous implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laboratory-assessed masticatory function (before treatment)
Number of subjects: 60
Study: 12089368

Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control (<120/80 mmHg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard blood pressure control (135-140/85-90 mmHg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 75
Study: 9583839

Group type: COMPARATOR
Intervention: Placebo (first 60 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Small supplement (0.93 micromol beta‐carotene/d, first 60 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Small supplement (0.93 micromol beta‐carotene/d, days 61-120)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Larger mixed carotenoid supplement (6.16 micromol beta‐carotene/d, days 101-120)
Number of subjects: 9
Study: 7643295

Group type: EXPERIMENTAL
Intervention: self‐report California Psychological Inventory
Number of subjects: 215
Study: 2565105

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 11
Study: 565216

Group type: EXPERIMENTAL
Intervention: Selenomethionine (Semet‐Se) 100 micrograms/day for 10-11 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium selenite (selenite‐Se) 100 micrograms/day for 10-11 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish (mackerel) selenium (fish‐Se) 65 micrograms/day for 4 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selenomethionine (Semet‐Se)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium selenite (selenite‐Se)
Number of subjects: 24
Study: 31414860

Group type: EXPERIMENTAL
Intervention: Naltrexone (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study: 29745298

Group type: EXPERIMENTAL
Intervention: Experimental protocol using TICCS for treatment guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 27515804

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26142493

Group type: EXPERIMENTAL
Intervention: Truview EVO2 video laryngoscope
Number of subjects: 42

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 42
Study: 24314930

Group type: EXPERIMENTAL
Intervention: Tacrolimus Medis 5 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prograf® 5 mg
Number of subjects: 36
Study: 21806769

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine/HCTZ 160/5/25 mg
Number of subjects: 488

Group type: COMPARATOR
Intervention: Losartan/HCTZ 100/25 mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine/HCTZ 320/10/25 mg (after titration)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Losartan/HCTZ switched to valsartan/amlodipine/HCTZ
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine group
Number of subjects: 488

Group type: COMPARATOR
Intervention: Losartan group
Number of subjects: 488
Study: 19114918

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32-33 degrees C) for 48 hours
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 28
Study: 16930934

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Subclinical hypothyroidism patients
Number of subjects: 42
Study: 15517750

Group type: EXPERIMENTAL
Intervention: SurePress Comfort compression stocking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard short-stretch bandage (Comprilan)
Number of subjects: 0
Study: 11742966

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3
Study: 9409548

Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8496313

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA; 20 mg/day) with GnRH analog (leuprolide acetate; 1 mg/day, sc)
Number of subjects: 16
Study: 3427250

Group type: EXPERIMENTAL
Intervention: Controlled drinking self-help manual
Number of subjects: 0

Group type: COMPARATOR
Intervention: General advice and information booklet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0
Study: 31603012

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT4): oral dexamethasone 40 mg for days 1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days, intravenous rituximab 100 mg for days 7, 14, 21, and 28
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT4)
Number of subjects: 40
Study: 30112726

Group type: EXPERIMENTAL
Intervention: DFN-11 (sumatriptan injection, 3 mg)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 27523501

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 331
Study: 25002671

Group type: EXPERIMENTAL
Intervention: In-person AFIX consultation
Number of subjects: 107443

Group type: EXPERIMENTAL
Intervention: Webinar AFIX consultation
Number of subjects: 107443

Group type: COMPARATOR
Intervention: Control (no consultation)
Number of subjects: 107443
Study: 22773180

Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Spectacles (SV)
Number of subjects: 61